Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proportion of ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC (ARES)

NCT07332975 is registered in ClinicalTrials.gov with University of Pittsburgh as lead sponsor.

NCT NCT07332975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proportion of ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC (ARES)
Lead sponsor
University of Pittsburgh
Phase
Observational
Overall status
Recruiting
Start date
January 20, 2026
Completion date
January 20, 2029
Enrollment
77 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer